merscov
highli
pathogen
viru
human
associ
high
morbid
case
fatal
inflammatori
respons
signific
impact
merscov
pathogenesi
diseas
outcom
howev
tcell
induc
immun
respons
acut
merscov
infect
bare
detect
potent
inhibit
effector
cell
downregul
antigen
present
local
pulmonari
immun
respons
particularli
immun
respons
acut
sever
merscov
infect
fulli
understood
studi
offer
first
insight
pulmonari
gene
express
profil
cytokineschemokin
respons
acut
merscov
infect
use
rt
profil
pcr
array
also
quantifi
express
level
primari
inflammatori
cytokineschemokin
result
show
downregul
inadequ
partial
immun
respons
high
express
level
inflammatori
cytokin
neutrophil
chemoattract
chemokin
lower
respiratori
tract
merscov
infect
patient
moreov
identifi
high
viral
load
includ
patient
also
observ
correl
inflammatori
cytokin
downregul
case
fatal
rate
respons
downregul
high
express
inflammatori
cytokin
high
viral
load
may
contribut
lung
inflamm
sever
infect
evolut
pneumonia
ard
higher
case
fatal
rate
studi
molecular
mechan
underli
regulatori
pathway
vital
activ
vaccin
develop
identif
novel
therapeut
strategi
middl
east
respiratori
syndrom
mer
novel
viral
respiratori
ill
caus
merscov
first
describ
june
patient
hospit
sign
sever
respiratori
tract
infect
patient
later
die
respiratori
renal
failur
accord
statist
provid
world
health
organ
june
total
laboratoryconfirm
case
human
merscov
infect
report
estim
death
countri
accumul
evid
suggest
merscov
infect
character
high
level
system
inflammatori
cytokineschemokin
well
immunopatholog
high
inflammatori
cytokin
chemokin
level
strongli
correl
poor
diseas
outcom
immunopatholog
massiv
infiltr
immun
inflammatori
cell
lung
moreov
stimul
variou
cytokin
chemokin
innat
immun
cell
associ
appear
cytokin
storm
occur
infect
pathogen
coronaviru
cov
influenza
viru
addit
infect
viral
bronchiol
pathogenesi
sever
immunopatholog
diseas
enhanc
respiratori
syncyti
viru
hrsv
infect
likewis
increas
level
inflammatori
cytokin
associ
tissu
damag
acut
inflammatori
respons
lead
mortal
sever
pathogenesi
well
induct
inflammatori
loop
merscov
evad
antagon
antivir
immun
respons
well
nuclear
signal
pathway
ifn
signal
cascad
diseas
pathogenesi
merscov
infect
complex
variou
factor
involv
onset
sever
pulmonari
damag
dissemin
viru
organ
cell
cytokin
play
key
role
antivir
immun
enhanc
toxic
effect
cell
stimul
nk
cell
contribut
regul
cellular
immun
cell
secret
mediat
humor
immun
respons
stimul
antibodi
product
imbalanc
cytokineschemokin
contribut
patholog
chang
ineffici
clear
infect
host
suscept
immunemedi
diseas
vivo
data
highlight
import
role
cell
control
reduc
pathogenesi
decreas
merscov
titer
report
describ
complet
cellular
immun
respons
lower
respiratori
tract
merscov
therefor
still
unclear
whether
thelper
induc
cytokineschemokin
benefici
harm
merscovinfect
patient
moreov
host
immun
respons
activ
lower
respiratori
tract
merscov
infect
also
remain
unclear
studi
offer
first
insight
pulmonari
molecular
gene
express
profil
cytokineschemokin
respons
acut
merscov
infect
use
rt
profil
pcr
also
describ
express
level
primari
inflammatori
cytokin
chemokin
lower
respiratori
tract
institut
review
board
king
fahad
medic
citi
review
approv
studi
protocol
irb
regist
number
handl
respiratori
sampl
well
aliquot
viral
cellular
rna
extract
execut
use
appropri
person
protect
equip
biosafeti
level
laboratori
riyadh
region
laboratori
ministri
health
riyadh
saudi
arabia
lower
respiratori
sampl
collect
merscov
posit
patient
healthi
noninfect
individu
exclud
effect
antivir
therapi
express
cytokineschemokin
understudi
sampl
collect
initi
antivir
treatment
merscov
sputum
sampl
collect
patient
ask
rins
mouth
gargl
water
twice
immedi
obtain
sampl
instruct
expector
saliva
postnas
discharg
contain
collect
reduc
possibl
contamin
upper
respiratori
tract
fluid
subsequ
patient
request
breath
expector
deep
cough
sputum
directli
steril
sputum
cup
screw
cap
tracheal
aspir
ta
collect
via
endotrach
tube
report
elsewher
bronchoalveolar
lavag
bal
collect
follow
standard
protocol
techniqu
sampl
procedur
previous
describ
first
bal
fluid
aliquot
recov
discard
reduc
crosscontamin
upper
respiratori
tract
fluid
order
exclud
effect
viral
coinfect
influenza
cytokineschemokin
express
level
merscov
posit
patient
screen
genexpert
flu
cepheid
sunnyval
ca
accord
instruct
sampl
centrifug
rpm
min
cellfre
supernat
frozen
use
subsequ
analysi
inflammatori
cytokin
chemokin
elisarray
well
merscov
viral
load
test
pellet
use
total
cellular
rna
extract
use
rneasi
mini
kit
qiagen
valencia
ca
detect
merscov
rna
concentr
lower
respiratori
tract
viral
rna
isol
lower
respiratori
specimen
use
qiaamp
viral
rna
extract
mini
kit
qiagen
accord
instruct
rna
dissolv
elut
buffer
store
separ
aliquot
intern
control
ic
includ
control
procedur
use
sampl
prepar
viral
rna
purif
extract
viral
rna
test
realtim
rtpcr
duplex
assay
target
upe
region
merscov
genom
use
merscov
rtpcr
kit
rtpcr
duplex
assay
system
involv
two
independ
assay
one
target
quantifi
region
upstream
e
gene
upe
target
open
read
frame
region
merscov
genom
analysi
perform
use
abi
appli
biosystem
main
human
proinflammatori
cytokin
chemokin
gmcsf
measur
lower
respiratori
sampl
merscov
infect
patient
healthi
noninfect
control
group
use
multianalyt
elisarray
qiagen
germantown
md
usa
accord
protocol
absorb
obtain
product
min
measur
nm
cytokin
chemokin
level
determin
compar
neg
assay
buffer
posit
control
cocktail
contain
standard
cytokin
chemokin
respect
presenc
determin
cytokinechemokin
base
absorb
valu
neg
control
mean
absorb
sampl
standard
calcul
replic
concentr
calcul
use
standard
curv
cytokinechemokin
level
express
pgml
pulmonari
express
gene
involv
respons
assess
cellular
rna
isol
lower
respiratori
tract
sampl
use
rneasi
mini
kit
qiagen
valencia
ca
concentr
puriti
rna
assess
use
thermoscientif
cdna
synthesi
genom
dna
elimin
perform
use
rt
firststrand
synthesi
kit
qiagen
germantown
md
usa
use
rna
mrna
express
level
immun
gene
measur
use
rt
pcr
profil
array
kit
qiagen
germantown
md
usa
abi
prism
system
appli
biosystem
rt
sybr
green
rox
qpcr
master
mix
qiagen
germantown
md
usa
briefli
cdna
templat
combin
rt
realtim
sybr
green
master
mix
rnasefre
water
final
reaction
volum
ad
well
rt
pcr
profil
array
cyclethreshold
ct
valu
obtain
use
constant
baselin
realtim
rtpcr
run
previous
describ
five
endogen
control
gene
provid
array
actb
gapdh
gusb
use
calcul
arithmet
mean
set
ct
valu
normal
onlin
rt
pcr
profil
data
pcr
array
analysi
softwar
use
identifi
appropri
refer
gene
use
normal
rtpcr
array
gene
express
data
realtim
rtpcr
array
result
analyz
use
onlin
rt
pcr
profil
data
pcr
array
analysi
softwar
http
dataanalysisqiagencompcrarrayanalysisphp
sampl
assess
revers
transcript
effici
pcr
array
reproduc
genom
dna
contamin
use
qualiti
control
function
softwar
experiment
gene
express
quantifi
calcul
normal
housekeep
gene
statist
analysi
perform
use
spss
version
spss
inc
chicago
il
variabl
compar
mer
cov
infect
patient
healthi
noninfect
control
ttest
oneway
anova
analysi
use
appropri
data
present
mean
standard
deviat
count
percentag
pvalu
consid
statist
signific
demograph
data
outcom
preexist
condit
underli
chronic
diseas
clinic
characterist
mer
cov
infect
patient
diseas
outcom
present
tabl
realtim
rtpcr
result
show
high
viral
load
merscov
patient
regardless
type
specimen
mean
merscov
rna
ct
valu
standard
deviat
upe
respect
tabl
viral
load
merscov
express
level
inflammatori
cytokin
chemokin
found
significantli
correl
case
fatal
merscov
infect
patient
p
furthermor
found
signific
correl
p
merscov
viral
load
express
level
inflammatori
cytokin
neutrophil
chemoattract
chemokin
influenza
coinfect
detect
among
merscov
posit
patient
lower
respiratori
tract
sampl
merscov
infect
patient
healthi
noninfect
control
use
quantifi
express
level
main
human
proinflammatori
cytokin
chemokin
gmcsf
among
panel
inflammatori
cytokineschemokin
mean
express
level
pgml
p
pgml
p
significantli
higher
lower
respiratori
tract
merscov
infect
patient
compar
healthi
noninfect
control
tabl
furthermor
result
show
signific
correl
il
p
p
level
case
fatal
merscov
infect
patient
express
level
detect
four
patient
express
level
increas
five
patient
express
found
significantli
increas
pgml
p
merscov
patient
compar
healthi
control
tabl
result
show
signific
correl
express
level
case
fatal
merscov
infect
patient
p
order
studi
pulmonari
respons
merscov
infect
patient
molecular
cytokinechemokin
profil
assess
use
rt
pcr
array
gene
least
twofold
chang
express
compar
housekeep
gene
select
analysi
sidebysid
analysi
data
deriv
rt
pcr
profil
pulmonari
respons
show
gene
encod
cytokin
chemokin
larg
downregul
lower
respiratori
tract
merscov
infect
patient
total
gene
involv
regul
immun
respons
downregul
merscov
infect
patient
tabl
mrna
express
level
cytokineschemokin
downregul
contrast
express
cytokinechemokin
mrna
name
upregul
tabl
regard
immun
respons
identifi
cytokin
chemokin
mrna
express
level
downregul
merscov
infect
patient
tabl
observ
modul
differ
respons
inflammatori
cytokineschemokin
express
level
merscov
infect
patient
underli
chronic
medic
condit
merscov
infect
patient
without
underli
chronic
medic
condit
diseas
outcom
well
immunopatholog
pathogenesi
merscov
sar
respiratori
viral
infect
human
anim
strongli
link
express
level
inflammatori
cytokin
chemokin
variou
cytokin
chemokin
innat
immun
cell
associ
immunopatholog
coronaviru
cov
influenza
viru
infect
studi
offer
first
insight
lung
molecular
gene
express
profil
cytokin
chemokin
respons
acut
merscov
infect
previou
studi
shown
dysregul
excess
immun
respons
may
caus
immunopatholog
fatal
diseas
direct
cytopath
effect
high
viru
titer
viral
evas
host
immun
respons
believ
play
major
role
sever
diseas
result
sarscov
merscov
infect
result
show
high
viral
load
ct
valu
merscov
infect
patient
regardless
specimen
type
tabl
sever
proinflammatori
cytokin
contribut
ard
pathogenesi
ard
shown
primari
caus
death
among
patient
sarscov
merscov
infect
studi
major
merscov
infect
patient
progress
ard
subsequ
develop
pneumonia
requir
admiss
intens
care
unit
icu
vitro
studi
reveal
merscov
induc
signific
delay
modif
express
ifn
proinflammatori
cytokin
includ
chemokin
result
show
high
express
level
lower
respiratori
tract
merscov
infect
patient
evid
studi
investig
sar
respiratori
syncyti
viru
hrsv
reveal
associ
acut
sar
infect
bronchiol
immunopatholog
diseas
enhanc
hrsv
infect
critic
chemokin
involv
neutrophil
recruit
activ
local
neutrophil
accumul
shown
induc
format
neutrophil
extracellular
trap
net
net
highli
immunogen
extrem
toxic
host
tissu
abl
directli
caus
inflamm
patholog
chang
epitheli
endotheli
cell
death
lung
net
increas
inflamm
stimul
express
lead
recruit
neutrophil
hypothes
high
express
level
may
caus
netosi
result
sever
merscov
infect
increas
immunopatholog
associ
tissu
damag
neutrophil
infiltr
acut
inflammatori
respons
higher
case
fatal
sever
respiratori
viral
infect
studi
high
express
level
measur
lower
respiratori
tract
merscov
infect
patient
previou
studi
shown
express
influenza
infect
increas
lung
inflamm
subsequ
treatment
antagonist
significantli
reduc
inflamm
lung
tissu
damag
suggest
critic
cytokin
contribut
lung
inflamm
likewis
anoth
studi
shown
mrna
level
upregul
cell
infect
merscov
andor
sarscov
inflammatori
cytokin
rapidli
induc
quickli
reach
high
level
respons
rang
stimul
pathogen
agent
mous
model
shown
key
player
trigger
neutrophil
inflamm
likewis
result
reveal
high
express
level
merscov
infect
patient
therefor
think
high
level
may
play
critic
role
immunopatholog
sever
case
fatal
merscov
infect
patient
establish
inflammatori
loop
activ
downstream
signal
enabl
interact
lead
product
thu
loop
continu
selfperpetu
inflamm
occur
result
extens
tissu
damag
patholog
chang
elev
level
acut
merscov
infect
may
caus
inflammatori
loop
contribut
extens
tissu
damag
patholog
chang
associ
diseas
import
note
express
level
time
monitor
differ
interv
studi
thu
propos
inflammatori
loop
may
generaliz
case
sever
diseas
patient
treat
antiinflammatoryantivir
drug
shown
effect
control
host
inflammatori
respons
antivir
treatment
associ
reduct
inflammatori
cytokin
level
steadi
improv
diseas
condit
pulmonari
function
consequ
studi
express
level
differ
interv
could
assist
better
understand
merscov
immunopatholog
specul
monitor
express
level
differ
time
point
merscov
infect
may
alter
propos
inflammatori
loop
import
innat
antivir
cytokin
high
level
detect
vitro
studi
sarscov
merscov
h
studi
induct
larg
absent
similarli
recent
studi
express
detect
patient
merscov
infect
acut
convalesc
stage
may
indic
limit
earli
vivo
respons
merscov
infect
one
explan
differ
vitro
vivo
studi
could
differ
kinet
merscov
respons
vitro
model
gradual
increas
gene
express
time
howev
like
explan
complex
interplay
target
cell
infect
merscov
replic
viral
load
time
sampl
collect
measur
cytokineschemokin
level
viral
load
singl
time
point
earli
phase
infect
assess
cytokineschemokin
concentr
viral
load
differ
time
point
merscov
infect
creat
kinet
profil
cytokineschemokin
might
yield
addit
inform
overal
distinct
respons
vitro
vivo
might
impact
vivo
pathogenesi
viral
amplif
tcell
immun
respons
respiratori
viral
infect
character
product
signatur
cytokin
cell
cell
balanc
respons
critic
outcom
viral
infect
surpris
found
express
gene
encod
cytokineschemokin
larg
downregul
lower
respiratori
tract
merscov
infect
patient
tabl
pulmonari
respons
show
downregul
gene
encod
cytokineschemokin
merscov
infect
patient
play
import
role
earli
immun
induc
apoptosi
infect
cell
stimul
natur
killer
nk
cell
studi
main
cytokin
mrna
express
level
downregul
lower
respiratori
tract
merscov
infect
patient
hand
cytokin
chemokin
overexpress
lung
merscov
infect
patient
tabl
regard
immun
respons
cytokin
downregul
cytokin
play
import
role
humor
immun
respons
promot
antibodi
product
merscov
infect
complet
downregul
respons
studi
could
detect
mrna
specif
antivir
immun
respons
merscov
infect
patient
reghunathan
et
al
also
found
strong
inflammatori
respons
acut
sar
despit
complet
downregul
mrna
express
gene
involv
specif
antivir
immun
respons
downregul
major
cytokineschemokin
contribut
patholog
chang
ineffici
clear
infect
host
suscept
immunemedi
diseas
upregul
cytokineschemokin
shown
play
import
role
virusinduc
immunopatholog
usual
associ
acut
lung
inflamm
associ
acut
lung
inflamm
addit
shown
enhanc
sever
hrsv
diseas
soc
protein
affect
antivir
signal
pathway
allow
virus
evad
host
immun
respons
facilit
viral
replic
moreov
suggest
shape
present
viral
diseas
previou
data
show
mrna
significantli
upregul
respons
suppress
soc
signal
improv
influenza
infect
inhibit
hrsv
replic
mrna
upregul
correl
hrsvdiseas
sever
antagon
reduc
patholog
morbid
mortal
influenza
infect
hrsv
infect
increas
associ
underli
patholog
addit
shown
block
reduc
immunopatholog
respiratori
viru
infect
therefor
think
overexpress
may
play
critic
role
immunopatholog
sever
case
fatal
merscov
infect
patient
factor
contribut
molecul
upregul
merscov
infect
studi
need
studi
previou
data
show
express
cell
alter
merscov
infect
merscov
could
persist
induc
express
proinflammatori
cytokineschemokin
would
upregul
molecul
enhanc
helper
cell
infect
express
high
level
net
format
could
import
effect
express
propos
mechan
explain
role
lower
respiratori
tract
cytokin
chemokin
acut
merscov
infect
recruit
activ
neutrophil
subsequ
activ
neutrophil
undergo
degranul
netosi
contribut
patholog
chang
lead
recruit
inflammatori
elev
acut
merscov
infect
may
caus
inflammatori
loop
contribut
extens
tissu
damag
patholog
chang
essenti
mediat
develop
pathogenesi
ard
moreov
overexpress
may
play
vital
role
sever
immunopatholog
case
fatal
merscov
infect
patient
import
note
sampl
studi
screen
abl
screen
respiratori
virus
viral
coinfect
could
result
specif
virusviru
interact
howev
inflammatori
respons
induc
one
viru
may
significantli
chang
infect
second
third
viru
examin
influenc
coinfect
respiratori
virus
cytokineschemokin
express
level
chang
immun
profil
merscov
infect
patient
due
respiratori
pathogen
unknown
howev
possibl
respiratori
viral
infect
screen
studi
might
skew
immun
profil
merscov
infect
patient
think
simultan
studi
variabl
ie
interplay
merscov
respiratori
virus
could
potenti
skew
data
like
requir
assess
alter
immun
profil
merscov
infect
patient
four
limit
studi
note
first
measur
cytokineschemokin
express
level
viral
load
singl
time
point
earli
phase
infect
assess
cytokineschemokin
express
level
viral
replic
differ
time
point
merscov
infect
creat
kinet
profil
might
yield
addit
inform
second
studi
design
includ
control
patient
infect
respiratori
viral
pathogen
third
screen
merscov
posit
sampl
screen
sampl
respiratori
virus
fourth
abl
recruit
health
noninfect
individu
similar
merscov
infect
patient
underli
diseasespreexist
condit
futur
studi
design
close
gap
need
consid
taken
togeth
high
express
inflammatori
cytokin
chemokin
lower
respiratori
tract
merscov
infect
patient
confirm
lung
immunopatholog
therefor
high
express
inflammatori
cytokin
downregul
immun
respons
lower
respiratori
tract
merscov
infect
patient
may
contribut
sever
infect
higher
case
fatal
lung
inflamm
immunopatholog
furthermor
high
level
inflammatori
cytokineschemokin
could
key
point
subsequ
develop
pneumonia
ard
merscov
infect
patient
character
pulmonari
respons
merscov
infect
could
valuabl
effect
vaccin
develop
novel
therapeut
strategi
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
